Glaxosmithkline Llc Drug Patent Portfolio
Glaxosmithkline Llc owns 6 orange book drugs protected by 11 US patents with Lamictal Cd having the least patent protection, holding only 1 patent. And Lamictal Odt with maximum patent protection, holding 3 patents. Given below is the list of Glaxosmithkline Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7919115 | Orally disintegrating tablet compositions of lamotrigine | 04 Jan, 2029 | Active |
| US8840925 | Orally disintegrating tablet compositions of lamotrigine | 02 Jul, 2028 | Active |
| US9339504 | Orally disintegrating tablet compositions of lamotrigine | 02 Jul, 2028 | Active |
| US8637512 | Formulations and method of treatment | 14 Jun, 2028 | Active |
| US9144547 | Oral dosage form for controlled drug release | 22 Sep, 2023 | Expired |
| US7927624 | Hydrophilic/lipophilic polymeric matrix dosage formulation | 02 Dec, 2021 | Expired |
| US8303986 | Hydrophilic/lipophilic polymeric matrix dosage formulation | 12 Apr, 2021 | Expired |
| US6649659 | Atovaquone pharmaceutical compositions | 10 Jan, 2017 | Expired |
| US6649659 | Atovaquone pharmaceutical compositions | 10 Jul, 2016 | Expired |
| US5681588 | Delayed release microtablet of β-phenylpropiophenone derivatives | 28 Oct, 2014 | Expired |
| US5698226 | Water-dispersible tablets | 29 Jul, 2012 | Expired |
Latest Legal Activities on Glaxosmithkline Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Glaxosmithkline Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 24 Jun, 2024 | US8303986 |
|
Expire Patent
Critical
| 22 May, 2023 | US7927624 |
|
Expire Patent
Critical
| 08 May, 2023 | US7919115 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9144547 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Dec, 2022 | US7927624 |
|
Maintenance Fee Reminder Mailed
Critical
| 21 Nov, 2022 | US7919115 (Litigated) |
|
Email Notification
Critical
| 27 Apr, 2022 | US7919115 (Litigated) |
| Mail PUB other miscellaneous communication to applicant | 25 Apr, 2022 | US7919115 (Litigated) |
| PUB Other miscellaneous communication to applicant | 21 Apr, 2022 | US7919115 (Litigated) |
| Letter of Express Abandonment Filed | 18 Apr, 2022 | US7919115 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Apr, 2020 | US8303986 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2019 | US9144547 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Oct, 2018 | US7927624 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2018 | US7919115 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Sep, 2015 | US9144547 |
Glaxosmithkline Llc's Drug Patent Litigations
Glaxosmithkline Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 25, 2002, against patent number US6649659. The petitioner , challenged the validity of this patent, with DEARN as the respondent. Click below to track the latest information on how companies are challenging Glaxosmithkline Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6649659 | April, 2002 |
Decision
(30 Jun, 2003)
| DEARN | |
Glaxosmithkline Llc's Family Patents
Glaxosmithkline Llc Drug List
Given below is the complete list of Glaxosmithkline Llc's drugs and the patents protecting them.
1. Lamictal Cd
Lamictal Cd is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5698226
(Pediatric)
| Water-dispersible tablets |
29 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Cd's drug page
2. Lamictal Odt
Lamictal Odt is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7919115 | Orally disintegrating tablet compositions of lamotrigine |
04 Jan, 2029
(3 years from now)
| Active |
| US8840925 | Orally disintegrating tablet compositions of lamotrigine |
02 Jul, 2028
(3 years from now)
| Active |
| US9339504 | Orally disintegrating tablet compositions of lamotrigine |
02 Jul, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Odt's drug page
3. Lamictal Xr
Lamictal Xr is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8637512 | Formulations and method of treatment |
14 Jun, 2028
(3 years from now)
| Active |
| US9144547 | Oral dosage form for controlled drug release |
22 Sep, 2023
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Xr's drug page
4. Mepron
Mepron is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6649659
(Pediatric)
| Atovaquone pharmaceutical compositions |
10 Jan, 2017
(8 years ago)
| Expired |
| US6649659 | Atovaquone pharmaceutical compositions |
10 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mepron's drug page
5. Requip Xl
Requip Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7927624 | Hydrophilic/lipophilic polymeric matrix dosage formulation |
02 Dec, 2021
(3 years ago)
| Expired |
| US8303986 | Hydrophilic/lipophilic polymeric matrix dosage formulation |
12 Apr, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Requip Xl's drug page
Explore Our Curated Drug Screens
6. Rythmol Sr
Rythmol Sr is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5681588 | Delayed release microtablet of β-phenylpropiophenone derivatives |
28 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rythmol Sr's drug page